Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.63 |
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.43 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4055815 | 0.87 | RAB9A (0.48) | MAPTPOLBRAB9AMEN1KMT2A | |
| SCHEMBL4058064 | 0.86 | MAPT (0.47) | MAPTPOLBRAB9AMEN1KMT2A | |
| SCHEMBL4064425 | 0.86 | MAPT (0.47) | MAPTPOLBRAB9AMEN1KMT2A | |
| SCHEMBL4055995 | 0.84 | MAPT (0.62) | MAPTPOLBRAB9AKMT2AATM | |
| SCHEMBL3773593 | 0.81 | MAPT (0.45) | MAPTPOLBRAB9AMEN1KMT2A | |
| SCHEMBL1265805 | 0.72 | MAPT (0.46) | MAPTPOLBRAB9AMEN1KMT2A | |
| SCHEMBL4060127 | 0.69 | MAPK1 (0.48) | MAPTPOLBRAB9AMEN1KMT2A | |
| SCHEMBL3913826 | 0.68 | MAPT (0.57) | MAPTPOLBRAB9AMEN1KMT2A | |
| SCHEMBL3821604 | 0.68 | MEN1 (0.45) | MAPTPOLBRAB9AMEN1KMT2A | |
| SCHEMBL4055825 | 0.68 | KMT2A (0.65) | MAPTPOLBRAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550473-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1590334-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050124640-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2004067516-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124640-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCQ, PRKCZ, PRKCH | MAPT 3633/4885POLB 181/4885RAB9A 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.